Those who had the foresight to invest in these two companies three years ago are sitting pretty right now. Both companies have soared over this period, with the former skyrocketing 2,280% and the latter gaining 631%. These two rising stars in the biotech industry have experienced significant clinical and regulatory progress, which has fueled their growth engines.
Even with these recent performances, Summit and Madrigal could have plenty more upside potential, so it’s not too late to invest in them. Here’s why.
This post originally appeared at The Motley Fool.